Tian Xu, Chen Wei-Qing, Liu Xiao-Ling, Pi Yuan-Ping, Chen Hui
Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment Key Laboratory for Biorheological Science and Technology of Ministry of Education (Chongqing University), Chongqing University Cancer Hospital & Chongqing Cancer Institute & Chongqing Cancer Hospital, Chongqing, China.
Medicine (Baltimore). 2018 May;97(21):e10839. doi: 10.1097/MD.0000000000010839.
Oral mucositis has been an extremely serious complication resulted from cytotoxic effects of the chemotherapy among cancer patients. Several randomized controlled trials investigated the efficacy of zinc sulfate in prevention of this morbid condition among cancer patients undergoing chemotherapy, however conclusive findings has not yet been generated. This systematic review will assess the efficacy and safety of oral zinc sulfate for chemotherapy-induced oral mucositis.
We will electronically search all potential citations in PubMed, EMBASE, and Cochrane Central Register of Controlled Trials (CENTRAL) from their inception to April 2018. The randomized controlled trials, which investigated the efficacy of oral zinc sulfate for chemotherapy-induced oral mucositis will be considered. We will assign 2 independent investigators to perform search, screen citations, extract data, and appraise risk of bias. And then, the primary investigator will adopt RevMan 5.3 software to complete all statistical analyses.
The findings from this systematic review and meta-analysis will be submitted to a peer-reviewed journal for publication. Moreover, we will disseminate all results in any topic-related conference.
This protocol has been registered with a number of CRD42018093605.
口腔黏膜炎一直是癌症患者化疗细胞毒性作用导致的极其严重的并发症。多项随机对照试验研究了硫酸锌在接受化疗的癌症患者中预防这种疾病状态的疗效,然而尚未得出确凿的结果。本系统评价将评估口服硫酸锌治疗化疗引起的口腔黏膜炎的疗效和安全性。
我们将通过电子检索从创刊至2018年4月期间PubMed、EMBASE和Cochrane对照试验中心注册库(CENTRAL)中的所有潜在文献。将纳入研究口服硫酸锌治疗化疗引起的口腔黏膜炎疗效的随机对照试验。我们将指定2名独立研究人员进行检索、筛选文献、提取数据并评估偏倚风险。然后,第一作者将采用RevMan 5.3软件完成所有统计分析。
本系统评价和荟萃分析的结果将提交给同行评审期刊发表。此外,我们将在任何相关主题会议上传播所有结果。
本方案已注册,注册号为CRD42018093605。